Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma.

Health technology assessment (Winchester, England)

Volumn 13 Suppl 2, Issue , 2009, Pages 41-48

  Boland, A ^a   Bagust, A ^b   Hockenhull, J ^b   Davis, H ^b   Chu, P ^b   Dickson, R ^b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; RITUXIMAB;

COMPARATIVE EFFECTIVENESS; COST BENEFIT ANALYSIS; DRUG RESISTANCE; ECONOMICS; FOLLICULAR LYMPHOMA; HUMAN; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; COMPARATIVE EFFECTIVENESS RESEARCH; COST-BENEFIT ANALYSIS; DRUG RESISTANCE, NEOPLASM; HUMANS; LYMPHOMA, FOLLICULAR; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE;

MLCS; MLOWN;

EID: 84879830998     PISSN: None     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta13suppl2/06     Document Type: Review

References (12)